Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success

Moderna's stock has been on a remarkable upward trajectory this year, surging over 600%. The fervor surrounding the company stems from its cancer vaccine, developed in collaboration with Merck, a drug known as Keytruda that has fetched billions for Merck. Early clinical trial results have been promising, with the vaccine, known as intismeran, displaying promising effectiveness in treating melanoma patients in conjunction with Keytruda.

The vaccine slashed the risk of mortality and melanoma recurrence by 42% compared to Keytruda alone. However, there may be a significant hurdle to its widespread success: its production process is highly personalized and labor-intensive, requiring six weeks of custom manufacturing. This likely contributes to a high cost, potentially limiting its economies of scale advantage.

While analysts project peak annual sales of over $5 billion for Moderna based just on melanoma treatment, investors may need to temper their expectations regarding the timeline and profitability of the vaccine. Despite an 800% surge in Moderna's stock value over the past year, the company's valuation is already around $90 billion, raising concerns about its near-term profitability.

While intismeran may also prove effective against other types of cancer, this remains uncertain at present. Growth investors eyeing Moderna's current valuation appear to be taking substantial risks due to the considerable uncertainty surrounding the vaccine's financial impact. As such, The Motley Fool recommends keeping an eye on Moderna's stock, as its current price point may be overvalued given the optimism surrounding its future growth prospects.